Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
INMB
INMB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INMB News
INmune Bio Reports $45.9M Loss in 2025 Earnings
Mar 31 2026
Yahoo Finance
INmune Bio Reports Disappointing FY Results
Mar 30 2026
seekingalpha
INmune Bio Reports Financial Results for FY 2025
Mar 30 2026
Yahoo Finance
INmune Bio to Announce FY Earnings on March 30
Mar 29 2026
seekingalpha
INmune Bio Hosts Webinar on Alzheimer's Treatment Pathway
Feb 23 2026
Newsfilter
INmune Bio to Host CORDStrom Webinar on RDEB Treatment
Feb 19 2026
Newsfilter
INmune Bio Receives FDA Support for Alzheimer’s Therapy
Feb 12 2026
stocktwits
INmune Bio Publishes Overview on Future Applications of MSC Therapies
Dec 05 2025
Globenewswire
INmune Bio Presents New XPro1595 Data for Alzheimer's Disease at CTAD
Dec 01 2025
Globenewswire
INmune Bio Successfully Completes Initial Commercial Pilot-Scale Production of CORDStrom™ at CGT Catapult
Sep 15 2025
Newsfilter
INmune Bio (INMB) Declines 23.8% Over the Past Month, But a Trend Reversal Could Be Imminent
Sep 08 2025
NASDAQ.COM
INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift
Aug 08 2025
SeekingAlpha
INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
Aug 04 2025
Newsfilter
INmune Bio gains as trial for prostate cancer therapy succeeds
Aug 04 2025
SeekingAlpha
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
Jul 31 2025
Newsfilter
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Jul 28 2025
Benzinga
Show More News
